Merck (MRK) Other Operating Expenses (2010 - 2026)
Merck (MRK) posted quarterly Other Operating Expenses of $4.3 billion for Q1 2026, up 28.04% year-over-year from $3.4 billion in Q1 2025, and down 55.42% quarter-over-quarter from $9.7 billion in Q4 2025.
Merck (MRK) Other Operating Expenses (2010 - 2026) Analysis & Trends
Merck (MRK) has reported Other Operating Expenses for 17 consecutive years, with $4.3 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Operating Expenses rose 28.04% year-over-year to $4.3 billion; the TTM figure through Mar 2026 stood at $21.2 billion (up 41.05% YoY), while the FY2025 annual figure was $16.5 billion, up 8.99% from the prior year.
- Other Operating Expenses retreated to $4.3 billion in Q1 2026 per MRK's latest filing, from $9.7 billion in the prior quarter.
- Across five years, Other Operating Expenses topped out at $9.7 billion in Q4 2025 and bottomed at $3.4 billion in Q1 2025.
- Historically, Other Operating Expenses has averaged $4.7 billion across 5 years, with a median of $4.0 billion in 2023.
- Annual changes were most pronounced in 2024 — Other Operating Expenses sank 51.28% — and 2025, when it soared 145.74%.
- Merck's Other Operating Expenses stood at $3.8 billion in 2022, then jumped by 113.27% to $8.1 billion in 2023, then slumped by 51.28% to $4.0 billion in 2024, then jumped by 145.74% to $9.7 billion in 2025, then tumbled by 55.42% to $4.3 billion in 2026.
- Business Quant data shows MRK's Other Operating Expenses at $4.3 billion in Q1 2026, $9.7 billion in Q4 2025, and $3.6 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.49 Bn |
| Mar 31, 2026 | 4.33 Bn |
| Dec 31, 2025 | 9.72 Bn |
| Sep 30, 2025 | 3.62 Bn |
| Jun 30, 2025 | 3.55 Bn |
| Mar 31, 2025 | 3.38 Bn |
| Dec 31, 2024 | 3.96 Bn |
| Sep 30, 2024 | 3.92 Bn |
| Jun 30, 2024 | 3.79 Bn |
| Mar 31, 2024 | 3.51 Bn |
| Dec 31, 2023 | 8.12 Bn |
| Sep 30, 2023 | 4.39 Bn |
| Jun 30, 2023 | 4.20 Bn |
| Mar 31, 2023 | 4.02 Bn |
| Dec 31, 2022 | 3.81 Bn |
| Sep 30, 2022 | 4.36 Bn |
| Jun 30, 2022 | 4.65 Bn |
| Mar 31, 2022 | 6.09 Bn |
| Dec 31, 2021 | 3.54 Bn |
| Sep 30, 2021 | 3.00 Bn |